Rinvoq denials in California external review
In the California DMHC record, independent physician reviewers decided 28 published external-review cases involving Rinvoqand overturned the plan’s denial in 82.1%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Conditions behind Rinvoq denials
| Category | Decisions | Overturned |
|---|---|---|
| Crohn's Disease | 11 | 63.6% |
| Ulcerative Colitis | 10 | 90% |
| Atopic Dermatitis | 3 | 100% |
| Rheumatoid Arthritis | 3 | 100% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 25 | 88% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 3 | 33.3% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: The patient is a 24-year-old female diagnosed with moderately to severely active seropositive (RF+/CCP+) rheumatoid arthritis. She was previously treated with methotrexate which failed to control her rheumatoid arthritis. The patient was noted to have a needle phobia. Due to the needle phobia the patient was not started on injectable or intravenous tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis. The patient was subsequently placed on Rinvoq 15mg daily with significant improvement in her joint pain, joint swelling and joint stiffness. On 11/21/2022, the patient reported improvement in bilateral foot, hand, knee, ankle, wrist and shoulder pain.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Rinvoq 15 mg ER tablets. The records provided for review document that this patient has a documented history of both ankylosing spondylitis and atopic dermatitis with involvement of 10% body surface area (BSA). Per review of the chart notes and an undated letter from the provider, the patient has been treated with and failed Taltz and Cosentyx. The patient is currently being treated with sulfasalazine for ankylosing spondylitis. The provider’s notes state that the patient has also tried and failed treatment with fluocinonide ointment, tacrolimus, triamcinolone ointment, and betamethasone. Given the patient’s concurrent diagnoses of both ankylosing spondylitis and atopic dermatitis, it is appropriate for the patient to be treated with Rinvoq, which is U.S.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Rinvoq 45 milligrams (mg) per day for more than 84 days. Findings: The physician reviewer found that Rinvoq has demonstrated safety and efficacy for the treatment of Crohn’s disease. However, the clinical trials using Rinvoq for induction and maintenance of remission of Crohn’s disease used a dosage of 45 mg once daily for 12 weeks for induction, followed by a maintenance dosage of 15 mg once daily or 30 mg once daily. The use of Rinvoq and other Janus kinase inhibitors may lead to significant and serious adverse effects, including bacterial, fungal, and viral infections. Notably, one study found that higher rates of skin cancer were observed in patients on Rinvoq 30 mg versus patients on Rinvoq 15 mg.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary:The parent of a patient has requested authorization and coverage for dual targeted therapy with Skyrizi (risankizumab) and Rinvoq (upadacitinib). A small retrospective study has demonstrated efficacy with combination biologic and JAK inhibitor therapy in select adult patients with medically complex Crohn’s disease. However, most patients in that study had undergone prior inflammatory bowel disease surgeries, including ileostomies. There is insufficient evidence supporting the safety and efficacy of dual targeted therapy with risankizumab and upadacitinib in pediatric patients with Crohn’s disease, including those with growth delay and persistent ileitis.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
Why plans deny Rinvoq — and what reviewed cases show
Rinvoq (upadacitinib) is FDA-approved for: moderately to severely active Crohn's disease in adults with inadequate response or intolerance to one or more TNF blockers; moderately to severely active ulcerative colitis in adults with inadequate response or intolerance to one or more TNF blockers; rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other indications outside IBD. An on-label indication can be important evidence when a denial frames the requested use as unproven or cosmetic.
TNF-blocker history not documented
For IBD, Rinvoq's own FDA label requires prior inadequate response or intolerance to a TNF blocker — so the plan's step-therapy demand and the label point the same direction. Most Rinvoq denials turn on the prior-auth request not documenting that TNF history, not on any dispute that you qualify.
JAK-inhibitor safety gatekeeping
Because of class-wide JAK safety warnings, some plans layer extra criteria (age, cardiovascular history, clot history) beyond the label. Criteria the plan can't tie to the label or to published guidance are challengeable — demand the criteria document.
Oral drug routed to the wrong benefit or tier
Unlike infused biologics, Rinvoq is an oral specialty drug — requests sometimes fail on specialty-tier, quantity-limit, or pharmacy-vs-medical-benefit plumbing rather than clinical criteria. These are exception-process problems, not medical-necessity fights.
The step-therapy exception here is usually just documentation: Rinvoq's IBD label already assumes TNF-blocker failure, so a prescriber statement laying out that history — submitted through the plan's formulary exception process — addresses the requirement on its own terms.
Evidence cited in overturned Rinvoq decisions
- Document the TNF-blocker history precisely: which agent(s), doses, duration, and whether the problem was inadequate response or intolerance — that single paragraph satisfies both the label and the step-therapy criteria.
- If the plan prefers a different post-TNF option, have your prescriber state the clinical reasons for a JAK inhibitor — oral administration, prior biologic immunogenicity, or the specifics of your disease course.
- For safety-based denials, ask which label contraindication or warning the plan believes applies to you — a generic class warning is not a patient-specific clinical reason.
- Both IBD indications are FDA-approved for adults after TNF-blocker failure — this is on-label sequencing, not experimental use.
The published California record contains 28 external-review decisions involving Rinvoq; 82.1% were overturned. This historical rate does not predict another case. For the full class-wide picture — step therapy, biosimilar switching, dose caps, and the record for every IBD biologic — see the Crohn’s & colitis biologic appeal guide.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Rinvoq, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY